GeminIQ Website Logo

Viewing TRAX free

Subscribe for full history, 90+ metrics, screener, watchlist...

First Tracks Biotherapeutics, Inc.

TRAX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Cash And Cash Equivalents At Carrying Value
168248
Assets Current
Assets Current
178289
Available For Sale Securities Debt Securities Curr…
038
Prepaid Expense And Other Assets Current
103
Property Plant And Equipment Net
11
Operating Lease Right Of Use Asset
40
Other Assets Noncurrent
00
Assets
183291
Liabilities And Stockhold…
Accounts Payable Current
37
Liabilities Current
Accrued Liabilities Current
726
Liabilities Current
1233
Operating Lease Liability Current
20
Operating Lease Liability Noncurrent
20
Members Capital
0258
Stockholders Equity
Stockholders Equity
169257
Accumulated Other Comprehensive Income Loss Net Of…
0-0
Liabilities And Stockholders Equity
183291

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
2026-8.59%6.28%163.11%---

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
14.28
8.74
Quick Ratio
13.50
8.65
Working Capital
165.30M
256.29M
Leverage & Debt
Debt to Equity
0.07
0.13
Debt Ratio
0.07
0.11
Valuation Metrics
P/B TTM
4.17
-
Market Cap
704.26M
-
Enterprise Value
536.24M
-
Calculated Values
Net Debt
-168.02M
-248.47M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-04-20Sale
Owner: Ecor1, Capital, Llc
Title: -
Shares: 4,705,575
Price/Share: $13.81
Value: $64,983,990.75
Shares Owned: 3,174,519
Relationship: TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

No institutional ownership data available.

First Tracks Biotherapeutics, Inc. (TRAX) — SEC Financial Statements & Analysis

First Tracks Biotherapeutics, Inc. (TRAX) is a pharmaceutical preparations company, incorporated in DE. First Tracks Biotherapeutics, Inc. trades on Nasdaq as: TRAX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), First Tracks Biotherapeutics, Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 4.17x (TTM), at a market cap of $704.26M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
0.07x
P/B TTM
4.17x
Market Cap
$704.26M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is First Tracks Biotherapeutics, Inc. in?

First Tracks Biotherapeutics, Inc. (TRAX) operates in the Pharmaceutical Preparations industry.

What is TRAX's market cap?

First Tracks Biotherapeutics, Inc. (TRAX) has a market capitalization of $704.26M as of 2026-06-30.

What exchange does TRAX trade on?

First Tracks Biotherapeutics, Inc. (TRAX) trades on the Nasdaq.

Where is First Tracks Biotherapeutics, Inc. incorporated?

First Tracks Biotherapeutics, Inc. is incorporated in DE.

Wall Street's data.
Main Street's price.